Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 16.17 | 13.08 | 11.86 | 22.80 | 24.43 | 32.52 | 45.09 | 9.32 | 33.32 | 21.50 | 21.91 | — | 81.36 | — | — | — | — | — | — | — | — |
| — | -59.8% | -73.7% | +144.6% | -26.7% | +51.2% | +105.8% | — | -59.1% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.41 | 3.87 | 4.72 | 7.99 | 6.68 | 9.28 | 10.57 | 8.97 | 10.21 | 6.31 | 4.76 | 3.46 | 3.11 | 3.42 | 3.23 | 3.94 | 2.90 | 2.87 | 3.08 | 2.42 | 1.83 |
| — | -58.2% | -55.3% | -10.9% | -34.6% | +46.9% | +121.9% | +159.6% | +228.3% | +84.8% | +47.7% | -12.2% | +7.1% | +19.2% | +4.8% | +62.9% | +58.9% | +0.3% | -2.9% | -28.4% | -64.2% | |
| P/B Ratio | 4.98 | 4.72 | 5.54 | 9.32 | 8.32 | 11.37 | 13.00 | 12.08 | 21.10 | 14.38 | 10.15 | 7.55 | 5.53 | 5.60 | 5.04 | 5.18 | 4.75 | 3.40 | 2.82 | 1.81 | 1.47 |
| — | -58.4% | -57.4% | -22.9% | -60.6% | -21.0% | +28.1% | +60.0% | +281.9% | +156.8% | +101.3% | +45.9% | +16.2% | +64.7% | +78.6% | +186.7% | +223.2% | +86.0% | +56.1% | -15.4% | -49.9% | |
| P/FCF | 80.81 | 17.67 | 9.70 | 32.18 | — | 60.47 | — | 22.21 | 51.03 | 15.53 | — | 15.57 | 18.63 | — | — | — | — | — | — | — | — |
| — | -70.8% | — | +44.9% | — | +289.3% | — | +42.7% | +173.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 11.23 | 8.90 | 10.69 | 17.13 | 17.01 | 25.20 | 33.00 | 26.05 | 29.57 | 16.73 | 17.30 | 17.00 | 21.24 | 140.11 | 168.25 | — | — | — | — | — | — |
| — | -64.7% | -67.6% | -34.2% | -42.5% | +50.6% | +90.8% | +53.2% | +39.2% | -88.1% | -89.7% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 11.70 | 9.30 | 9.41 | 17.56 | 18.34 | 26.95 | 34.33 | 27.91 | 30.55 | 17.41 | 18.68 | — | 25.54 | — | — | — | — | — | — | — | — |
| — | -65.5% | -72.6% | -37.1% | -40.0% | +54.8% | +83.8% | — | +19.6% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.4% | 69.4% | 70.5% | 63.8% | 56.3% | 55.1% | 53.2% | 53.9% | 49.8% | 53.6% | 47.8% | 42.1% | 36.6% | 27.8% | 29.0% | 28.4% | 23.5% | 22.9% | 12.6% | 13.3% | 1.9% |
| — | +25.8% | +32.5% | +18.5% | +13.2% | +2.8% | +11.4% | +28.1% | +35.9% | +93.1% | +64.6% | +48.3% | +55.9% | +21.1% | +130.6% | +113.1% | +1161.3% | +507.8% | +217.3% | +136.0% | +112.1% | |
| Operating Margin | 37.5% | 42.2% | 43.9% | 45.1% | 38.0% | 35.1% | 30.4% | 32.6% | 33.1% | 36.6% | 26.7% | 19.3% | 12.9% | -0.8% | -1.4% | -12.1% | -22.7% | -27.1% | -50.9% | -50.0% | -69.8% |
| — | +20.2% | +44.6% | +38.3% | +14.9% | -4.1% | +14.0% | +69.3% | +156.2% | +4748.7% | +1965.7% | +258.9% | +156.9% | +97.1% | +97.2% | +75.8% | +67.5% | +69.0% | +46.1% | +59.5% | +48.0% | |
| Net Margin | 28.8% | 30.4% | 39.6% | 35.5% | 27.1% | 28.1% | 23.4% | 95.2% | 30.0% | 29.9% | 21.7% | -23.9% | 3.8% | -10.6% | -11.9% | -24.5% | -36.3% | -40.6% | -85.9% | -63.1% | -85.7% |
| — | +8.4% | +68.9% | -62.7% | -9.4% | -6.2% | +7.8% | +498.7% | +685.9% | +382.3% | +282.3% | +2.4% | +110.5% | +73.9% | +86.1% | +61.2% | +57.7% | +61.7% | +25.0% | +54.6% | +48.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 35.6% | 9.5% | 10.4% | 10.9% | 8.8% | 8.9% | 7.4% | 38.5% | 17.1% | 18.8% | 12.3% | -12.3% | 1.7% | -4.4% | -4.6% | -9.7% | -13.9% | -11.4% | -18.7% | -13.6% | -16.5% |
| — | +6.8% | +40.3% | -71.8% | -48.6% | -52.7% | -39.6% | +412.9% | +893.6% | +530.3% | +370.2% | -27.0% | +112.4% | +61.8% | +75.5% | +29.0% | +16.0% | +32.4% | -1.9% | +43.9% | +27.6% | |
| ROA | 26.4% | 5.6% | 7.0% | 8.3% | 6.5% | 6.4% | 5.4% | 25.5% | 9.4% | 8.8% | 5.2% | -5.2% | 0.7% | -1.9% | -2.0% | -3.8% | -5.0% | -4.6% | -8.6% | -6.5% | -7.5% |
| — | -12.4% | +30.6% | -67.5% | -31.0% | -27.4% | +2.8% | +589.1% | +1163.1% | +573.2% | +365.8% | -38.0% | +114.9% | +59.1% | +77.0% | +41.7% | +33.6% | +43.6% | -3.2% | +33.7% | +15.3% | |
| ROIC | 36.0% | 8.4% | 8.1% | 10.2% | 9.1% | 8.3% | 7.4% | 9.8% | 11.9% | 12.0% | 6.9% | 4.7% | 2.8% | -0.2% | -0.3% | -2.1% | -3.2% | -3.3% | -5.6% | -5.4% | -6.4% |
| — | +1.9% | +10.8% | +3.8% | -24.1% | -30.9% | +6.7% | +109.8% | +327.1% | +7995.9% | +2653.6% | +325.9% | +186.3% | +95.4% | +95.2% | +61.9% | +49.0% | +54.6% | +30.9% | +49.0% | +34.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.50 | 0.52 | 0.17 | 0.19 | 0.21 | 0.22 | 0.24 | 0.48 | 0.75 | 0.92 | 1.05 | 1.01 | 1.03 | 1.07 | 1.02 | 1.52 | 1.32 | 1.15 | 0.73 | 0.99 |
| — | +137.3% | +138.4% | -28.9% | -59.9% | -72.0% | -76.1% | -77.5% | -52.4% | -27.3% | -13.9% | +2.9% | -33.6% | -21.9% | -7.3% | +39.4% | +53.6% | +45.6% | +29.5% | -34.1% | -29.4% | |
| Debt / EBITDA | 0.40 | 3.64 | 3.92 | 1.23 | 1.57 | 1.87 | 2.23 | 2.04 | 2.68 | 3.43 | 5.91 | 8.65 | 14.19 | 93.24 | 127.64 | — | — | — | — | — | — |
| — | +94.6% | +76.2% | -39.5% | -41.5% | -45.5% | -62.3% | -76.4% | -81.1% | -96.3% | -95.4% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.71 | 6.97 | 6.95 | 6.71 | 7.13 | 5.33 | 6.58 | 5.97 | 7.09 | 6.87 | 5.21 | 5.16 | 6.54 | 6.35 | 7.19 | 6.89 | 5.04 | 7.94 | 7.60 | 6.87 | 5.41 |
| — | +30.8% | +5.7% | +12.4% | +0.6% | -22.4% | +26.3% | +15.6% | +8.4% | +8.3% | -27.6% | -25.1% | +29.7% | -20.0% | -5.3% | +0.2% | -6.7% | -15.8% | -9.1% | -10.9% | -36.2% | |
| Quick Ratio | 3.74 | 3.81 | 3.93 | 3.74 | 3.65 | 2.78 | 3.36 | 2.90 | 3.26 | 2.80 | 1.86 | 1.69 | 2.64 | 2.49 | 2.73 | 2.73 | 1.38 | 2.73 | 3.19 | 2.77 | 1.88 |
| — | +37.3% | +17.1% | +28.9% | +11.8% | -1.0% | +80.6% | +71.8% | +23.4% | +12.6% | -31.8% | -38.1% | +92.0% | -8.9% | -14.5% | -1.3% | -26.6% | -30.7% | -18.7% | -23.6% | -55.7% | |
| Interest Coverage | 26.69 | 15.67 | 28.20 | 38.88 | 29.37 | 22.86 | 17.94 | 13.06 | 11.50 | 10.48 | 5.88 | -1.84 | 1.40 | -0.01 | -0.11 | -1.13 | -1.67 | -2.01 | -6.38 | -4.02 | -4.37 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADMA stock.
ADMA Biologics, Inc.'s current P/E is 16.2x. The average P/E over the last 4 quarters is 18.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ADMA Biologics, Inc.'s current operating margin is 37.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ADMA Biologics, Inc.'s business trajectory between earnings reports.